Cyclohexetine Capsules

Not yet clear.

Erythromycin cyclic 11,12-carbonate.

This product is a white round biconvex tablet.

This product is mainly used for 1. Pneumonia caused by Mycoplasma hepatitis, Legionella pneumophila and Chlamydia pneumoniae. 2. Skin and soft tissue infections such as furuncle, acne, impetigo, cellulitis, eczema and other skin and soft tissue infections when there is no effective local treatment or other antibiotics cannot be used (such as infections caused by non-penicillin-sensitive Staphylococcus and penicillin-allergic patients). 3. Infections caused by mycoplasma, chlamydia, and Neisseria gonorrhoeae: such as non-gonococcal urethritis and gonorrhea. 4. Enteritis caused by Campylobacter. 5. Gastritis caused by Helicobacter pylori. 6. Whooping cough in children.

Oral administration, on an empty stomach, 3 hours before or after meals, once every 12 hours. Adults: 1-2 capsules (250-500 mg) each time, twice a day, for 5-10 days; Children: 15 mg/kg body weight, once every 12 hours.

The incidence of adverse reactions of this product is low. A small number of patients may experience abdominal discomfort, nausea, vomiting, diarrhea, skin flushing, eosinophilia, and fever. A very small number of patients may experience reversible hearing loss, pseudomembranous colitis, and liver damage. Long-term and repeated use of this product can lead to overgrowth of non-sensitive bacteria (Clostridium difficile) and mold (Candida albicans).

It is contraindicated in patients who are allergic to macrolide drugs.

Precautions for children: See Dosage and Administration. Precautions for pregnancy and lactation: Use with caution in pregnant or lactating women. Precautions for the elderly: Follow doctor's advice.

(1) High-dose NSAIDs including salicylates: The simultaneous use of more than one NSAID may increase the likelihood of gastrointestinal ulcers and bleeding through synergistic effects. (2) Oral anticoagulants, ampicillin: Systemic use of heparin and thrombolytics may increase the likelihood of bleeding. If the above-mentioned combined use is unavoidable, the effects of anticoagulants must be closely monitored. (3) Lithium: It has been reported that NSAIDs can increase the plasma concentration of lithium. Therefore, it is recommended to monitor plasma lithium levels when starting, adjusting and stopping meloxicam tablets. (4) Methotrexate: Similar to other NSAIDs, meloxicam tablets can increase the blood toxicity of methotrexate. In this case, it is recommended to strictly monitor blood cell counts. (5) Contraception: It has been reported that NSAIDs can reduce the effectiveness of intrauterine contraceptive devices. (6)

seal.

0.25g

24 months

Bright Future Pharmaceutical(Hainan) Co., Ltd.

• Founded in:

  1992-10-12

• Address:

  No. 2, Yaogu 1st Road, Yaogu Industrial Park, Haikou National High-tech Industrial Development Zone

• Tax NO.:

  914600009840920311

• Registered Funds:

  60 million yuan

• Website:

  Log in to view

• Email:

  Log in to view